文献速递脊柱关节炎

脊柱关节炎与骨关节炎患者使用特定非甾体抗炎药的心肌梗死风险

Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis.
PubMed 文献 · Ann Rheum Dis · 2018-04-19

基于THIN数据库的巢式病例对照研究,纳入8140例脊柱关节炎和244339例骨关节炎患者,分别有115例和6287例心肌梗死病例。脊柱关节炎患者当前使用双氯芬酸与心肌梗死风险升高相关(OR 3.32,95%CI 1.57-7.03),萘普生无关联(OR 1.19,95%CI 0.53-2.68)。脊柱关节炎/双氯芬酸相对骨关节炎/双氯芬酸的OR比值为2.64(95%CI 1.24-5.58)。

要点

  • 脊柱关节炎患者当前使用双氯芬酸与心肌梗死风险升高相关(OR 3.32,95%CI 1.57-7.03)。
  • 萘普生使用与心肌梗死风险升高无关联(OR 1.19,95%CI 0.53-2.68)。
  • 脊柱关节炎中双氯芬酸的心肌梗死风险模式与骨关节炎不同(OR比值2.64,95%CI 1.24-5.58)。

核心结论

  • 脊柱关节炎患者当前使用双氯芬酸与心肌梗死风险升高相关,但萘普生无此关联。
  • 脊柱关节炎中双氯芬酸相关的心肌梗死风险似乎与骨关节炎不同。

研究设计与样本

  • 使用健康改善网络(THIN)数据库进行的巢式病例对照研究。
  • 基础队列为有超过1次非甾体抗炎药处方且无心肌梗死史的成人新发脊柱关节炎或骨关节炎患者。
  • 脊柱关节炎队列8140例,骨关节炎队列244339例;每个心肌梗死病例匹配4例无心肌梗死对照。
  • 非甾体抗炎药使用分类为:当前(处方日期在索引日期前0-180天)、近期(181-365天)或远期(超过365天)。
  • 采用条件逻辑回归比较当前或近期使用非甾体抗炎药相对于远期使用任何非甾体抗炎药的比值比,并特别考虑双氯芬酸和萘普生。

主要发现

  • 脊柱关节炎队列中发生115例心肌梗死,骨关节炎队列中发生6287例心肌梗死。
  • 脊柱关节炎患者当前使用双氯芬酸与心肌梗死相关,调整OR为3.32(95%CI 1.57-7.03)。
  • 脊柱关节炎患者使用萘普生与心肌梗死风险升高无关联,调整OR为1.19(95%CI 0.53-2.68)。
  • 脊柱关节炎/双氯芬酸相对骨关节炎/双氯芬酸的OR比值为2.64(95%CI 1.24-5.58)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Spondyloarthritis (SpA) is associated with an increased risk of myocardial infarction (MI) due to underlying inflammation and possibly due to medications such as certain non-steroidal anti-inflammatory drugs (NSAIDs). We sought to describe MI risk among patients with SpA who were prescribed NSAIDs, and to compare the pattern of risk in SpA with that in osteoarthritis (OA). METHODS: Nested case-control studies were performed using The Health Improvement Network (THIN). Underlying cohorts included adults with incident SpA or OA who had >1 NSAID prescription and no history of MI. Within each cohort, we matched each MI case to four controls without MI. NSAID use was categorised as: (a) current (prescription date 0-180 days prior to index date), (b) recent (181-365 days) or (c) remote (>365 days). We performed conditional logistic regression to compare the odds of current or recent NSAID use relative to remote use of any NSAID, considering diclofenac and naproxen specifically. RESULTS: Within the SpA cohort of 8140 and the OA cohort of 244 339, there were 115 and 6287 MI cases, respectively. After adjustment, current diclofenac use in SpA was associated with an OR of 3.32 (95% CI 1.57 to 7.03) for MI. Naproxen was not associated with any increase (adjusted OR 1.19, 95% CI 0.53 to 2.68). A ratio of ORs for SpA/diclofenac relative to OA/diclofenac was 2.64 (95% CI 1.24 to 5.58). CONCLUSIONS: MI risk in SpA is increased among current users of diclofenac, but not naproxen. The MI risk with diclofenac in SpA appears to differ from that in OA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Dubreuil M, Louie-Gao Q, Peloquin CE, et al. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis. 2018. PMID: 29674321. doi:10.1136/annrheumdis-2018-213089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。